Akeso, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jill Wu from CMB International Securities maintained a Buy rating on the stock and has a HK$182.12 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jill Wu’s rating is based on Akeso, Inc.’s strong sales performance and strategic advancements in their product pipeline. The company reported a significant increase in product sales during the first half of 2025, driven by the inclusion of key products in the National Reimbursement Drug List (NRDL), which is expected to further boost sales in the coming years. Additionally, Akeso has demonstrated improved cost efficiency, with reduced selling and R&D expenses as a percentage of sales.
Moreover, the positive outcomes from the China HARMONi-A study for AK112, particularly its overall survival benefit in non-small cell lung cancer, enhance the potential for successful global trials. Akeso is also advancing the global development of AK104, with multiple ongoing trials and plans for further expansion. The company’s efforts to diversify its pipeline with early-stage ADC programs and the potential for strategic partnerships further support the Buy rating. These factors, along with anticipated data releases at upcoming conferences, underpin the optimism for Akeso’s future growth and market position.